Research
Hormonal
GLP-1 receptor agonists (RAs) have revolutionized treatment for type 2 diabetes mellitus and its comorbidities, including obesity and cardiovascular disease.
GLP-1 RAs should be considered as a treatment option for managing type 2 diabetes and associated conditions.
StrongSupportsmedium confidence
In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease.
Why this rating
The claim is based on a comprehensive overview of the GLP-1 RA class.
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →